SELLAS Life Sciences Group, Inc. (NasdaqCM: SLS)
Health Care · Biotechnology · US
$11.94
+2.49% today · +514.8% 1Y
SELLAS Life Sciences Group, Inc. (NasdaqCM: SLS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.35B and employs 13 people.
Over the last twelve months the share price has gained 514.8%, trading between 1.39 and 15.88.
Tweenvest scores SELLAS Life Sciences Group, Inc. across four factors: quality 44/100, value 67/100. Its strongest factor is value.
SLS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.35B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.21
- Dividend yield
- —
- Beta (5Y)
- 2.57
- 52-week high
- $15.88
- 52-week low
- $1.39
- Avg volume (3M)
- —
- Shares outstanding
- 201.95M
- Employees
- 13
- Next earnings
- —
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
- ISIN
- US81642T2096
- Listed since
- Mar 12, 2008
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Beam Therapeutics Inc.NasdaqGS: BEAM | $2.57B | $25.56 | -0.54% |
| Sinocelltech Group LimitedSHSE: 688520 | $2.54B | CN¥36.22 | -2.24% |
| Zealand Pharma A/SCPSE: ZEAL | $2.43B | Dkr234.80 | -1.34% |
| Disc Medicine, Inc.NasdaqGM: IRON | $2.38B | $61.06 | -1.61% |
| Celldex Therapeutics, Inc.NasdaqCM: CLDX | $2.35B | $29.43 | -1.54% |
| Recursion Pharmaceuticals, Inc.NasdaqGS: RXRX | $2.34B | $3.99 | -8.49% |
| PharmaResearch Co., Ltd.KOSDAQ: A214450 | $2.34B | ₩302,500.00 | -1.14% |
| ADMA Biologics, Inc.NasdaqGM: ADMA | $2.32B | $10.30 | -0.63% |
Figures last refreshed Oct 11, 2026.